The insurance industry is likely to find it more difficult to use genetic data on disease susceptibility than some of its critics claim. But it is already contesting demands for strict controls on the way this data is used.
This is a preview of subscription content, log in via an institution to check access.
Author information
Author notes
with additional reports from Sally Lehrman in San Francisco, Quirin Schiermeier in Munich, Declan Butler in Paris and Richard Nathan in Tokyo.
- Ehsan Masood
Rights and permissions
About this article
Cite this article
Masood, E. Gene tests: who benefits from risk?. Nature 379, 389–390 (1996). https://doi.org/10.1038/379389a0
Issue Date:
DOI: https://doi.org/10.1038/379389a0
- Springer Nature Limited
This article is cited by
-
Awareness of Societal Issues Among High School Biology Teachers Teaching Genetics
Journal of Science Education and Technology (2005)
-
Practice parameters for the identification and testing of patients at risk for dominantly inherited colorectal cancer—supporting documentation
Diseases of the Colon & Rectum (2001)
-
Genomanalyse: Fluch oder Segen für die Versicherungswirtschaft?
Zeitschrift für die gesamte Versicherungswissenschaft (1999)